대표적인 구강 및 비강 세정제의 Coronavirus Disease 2019 (COVID-19) 적용 연구의 현황

키워드

참고문헌 (66)

1. Whitworth J, "COVID-19 : a fast evolving pandemic", Trans R Soc Trop Med Hyg, 114(4), pp.241~248 (2020)
2. Chan JFW, "A familial cluster of pneumonia associated with the 2019novel coronavirus indicating person-to-person transmission : a study of a family cluster", Lancet, 395(10223), pp.514~523 (2020)
3. Ather A, "Coronavirus disease 19(COVID-19) : implications for clinical dental care", J Endod, 46(5), pp.584~595 (2020)
4. Rothe C, "Transmission of 2019-nCoV infection from an asymptomatic contact in Germany", N Engl J Med, 382(10), pp.970~971 (2020)
5. Zou L, "SARS-CoV-2 viral load in upper respiratory specimens of infected patients", N Engl J Med, 382(12), pp.1177~1179 (2020)
6. Hamming I, "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis", J Pathol, 203(2), pp.631~637 (2004)
7. Ahn JH, "Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19", J Clin Invest, 131(13), pp.e148517~ (2021)
8. Carrouel F, "COVID-19 : a recommendation to examine the effect of mouthrinses with β-cyclodextrin combined with citrox in preventing infection and progression", J Clin Med, 9(4), pp.1126~ (2020)
9. O’Donnell VB, "Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection", Function, 1(1) (2020)
10. Mateos-Moreno MV, "Oral antiseptics against coronavirus : in-vitro and clinical evidence", J Hosp Infect, 113, pp.30~43 (2021)
11. World Health Organization, "Considerations for the provision of essential oral health services in the context of COVID-19:interim guidance", World Health Organization, ~ (2020)
12. Shang J, "Cell entry mechanisms of SARS-CoV-2", Proc Natl Acad Sci USA, 117(21), pp.11727~11734 (2020)
13. Xu H, "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa", Int J Oral Sci, 12(1), pp.8~ (2020)
14. Zupin L, "Is FURIN gene expression in salivary glands related to SARS-CoV-2 infectivity through saliva?", J Clin Pathol, 74(4), pp.209~211 (2021)
15. Sungnak W, "SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes", Nat Med, 26(5), pp.681~687 (2020)
16. To KKW, "Consistent detection of 2019 novel coronavirus in saliva", Clin Infect Dis, 71(15), pp.841~843 (2020)
17. 윤진구, "Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva", Journal of Korean Medical Science, 35(20), pp.1~6 (2020), 대한의학회[DOI]
18. Baghizadeh Fini M, "Oral saliva and COVID-19", Oral Oncol, pp.104821~ (2020)
19. Carrouel F, "Antiviral activity of reagents in mouth rinses against SARS-CoV-2", J Dent Res, 100(2), pp.124~132 (2021)
20. Jayaweera M, "Transmission of COVID-19 virus by droplets and aerosols : a critical review on the unresolved dichotomy", Environ Res, 188, pp.109819~ (2020)
21. Fini MB, "What dentists need to know about COVID-19", Oral Oncol, 105, pp.104741~ (2020)
22. Xu J, "Salivary glands : potential reservoirs for COVID-19 asymptomatic infection", J Dent Res, 99(8), pp.989~ (2020)
23. Nair B, "Final report on the safety assessment of polyvinylpyrrolidone(PVP)", Int J Toxicol, 17(4_suppl), pp.95~130 (1998)
24. Nagatake T, "Prevention of respiratory infections by povidone-iodine gargle", Dermatology, 204(Suppl 1), pp.32~36 (2002)
25. Kawana R, "Inactivation of human viruses by povidone-iodine in comparison with other antiseptics", Dermatology, 195(Suppl 2), pp.29~35 (1997)
26. Anderson DE, "Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease", Infect Dis Ther, 9(3), pp.669~675 (2020)
27. Hassandarvish P, "Povidone iodine gargle and mouthwash", Br Dent J, 228(12), pp.900~ (2020)
28. Bidra AS, "Comparison of in vitro inactivation of SARS CoV-2 with hydrogen peroxide and povidone-iodine oral antiseptic rinses", J Prosthodont, 29(7), pp.599~603 (2020)
29. Shiraishi T, "Evaluation of the bactericidal activity of povidone-iodine and commercially available gargle preparations", Dermatology, 204(suppl 1), pp.37~41 (2002)
30. Lachapelle JM, "A comparison of the irritant and allergenic properties of antiseptics", Eur J Dermatol, 24(1), pp.3~9 (2014)
31. Frank S, "Povidone-iodine use in sinonasal and oral cavities : a review of safety in the COVID-19 era", Ear Nose Throat J, 99(9), pp.586~593 (2020)
32. Tsuda S, "Topical povidone iodine inhibits bacterial growth in the oral cavity of patients on mechanical ventilation : a randomized controlled study", BMC Oral Health, 20(1), pp.1~8 (2020)
33. Liang B, "In-vivo toxicity studies and in-vitro inactivation of SARSCoV-2 by povidone-iodine in-situ gel forming formulations", bioRxiv, ~ (2020)
34. Frank S, "In vitro efficacy of a povidone-iodine nasal antiseptic for rapid inactivation of SARS-CoV-2", JAMA Otolaryngol Head Neck Surg, 146(11), pp.1054~1058 (2020)
35. Gray PEA, "Recurrent anaphylaxis caused by topical povidone-iodine(betadine)", J Paediatr Child Health, 49(6), pp.506~507 (2013)
36. Lucía Martínez Lamas, "Is povidone iodine mouthwash effective against SARS‐CoV‐2? First in vivo tests", Oral Diseases (2020), Wiley[DOI]
37. Seneviratne CJ, "Efficacy of commercial mouth-rinses on SARSCoV-2 viral load in saliva : randomized control trial in Singapore", Infection, 49(2), pp.305~311 (2021)
38. Guenezan J, "Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19 : a randomized clinical trial", JAMA Otolaryngol Head Neck Surg, 147(4), pp.400~401 (2021)
39. Bernstein D, "In vitro virucidal effectiveness of a 0. 12%-chlorhexidine gluconate mouthrinse", J Dent Res, 69(3), pp.874~876 (1990)
40. Hidalgo E, "Mechanisms underlying chlorhexidine-induced cytotoxicity", Toxicol In Vitro, 15(4-5), pp.271~276 (2001)
41. Herrera D, "Is the oral cavity relevant in SARS-CoV-2 pandemic?", Clin Oral Investig, 24(8), pp.2925~2930 (2020)
42. Peng X, "Transmission routes of 2019-nCoV and controls in dental practice", Int J Oral Sci, 12(1), pp.9~ (2020)
43. Huang YH, "Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients", J Med Virol, 93(7), pp.4370~4373 (2021)
44. de Paula Eduardo F, "Salivary SARS-CoV-2 load reduction with mouthwash use : a randomized pilot clinical trial", Heliyon, pp.e07346~ (2021)
45. Segers P, "Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate : a randomized controlled trial", JAMA, 296(20), pp.2460~2466 (2006)
46. Chen MH, "The effectiveness of mouthwash against SARS-CoV-2 infection: a review of scientific and clinical evidence", J Formos Med Assoc (2021)
47. Meyers C, "Lowering the transmission and spread of human coronavirus", J Med Virol, 93(3), pp.1605~1612 (2021)
48. Komine A, "Virucidal activity of oral care products against SARS-CoV-2 in vitro", J Oral Maxillofac Surg Med Pathol, 33(4), pp.475~477 (2021)
49. Dev Kumar G, "Biocides and novel antimicrobial agents for the mitigation of coronaviruses", Front Microbiol, 11, pp.1351~ (2020)
50. Omidbakhsh N, "Broad-spectrum microbicidal activity, toxicologic assessment, and materials compatibility of a new generation of accelerated hydrogen peroxide-based environmental surface disinfectant", Am J Infect Control, 34(5), pp.251~257 (2006)
51. Caruso AA, "Might hydrogen peroxide reduce the hospitalization rate and complications of SARS-CoV-2 infection?", Infect Control Hosp Epidemiol, 41(11), pp.1360~1361 (2020)
52. Meister TL, "Virucidal efficacy of different oral rinses against severe acute respiratory syndrome coronavirus 2", J Infect Dis, 222(8), pp.1289~1292 (2020)
53. Gottsauner MJ, "A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2", Clin Oral Investig, 24(10), pp.3707~3713 (2020)
54. Asif M, "COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties", Inflammopharmacology, pp.1~9 (2020)
55. Burton MJ, "Antimicrobial mouthwashes(gargling)and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them", Cochrane Database Syst Rev, 9(9), pp.CD013627~ (2020)
56. Singh S, "Nasopharyngeal wash in preventing and treating upper respiratory tract infections: could it prevent COVID-19?", Lung India, 37(3), pp.246~251 (2020)
57. Machado RRG, "Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay", bioRxiv, ~ (2020)
58. Knowles MR, "Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects", J Clin Invest, 100(10), pp.2588~2595 (1997)
59. Tarran R, "The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition", J Gen Physiol, 118(2), pp.223~236 (2001)
60. Ramalingam S, "Antiviral innate immune response in non-myeloid cells is augmented by chloride ions via an increase in intracellular hypochlorous acid levels", Sci Rep, 8(1), pp.13630~ (2018)
61. Ramalingam S, "Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19", J Glob Health, 10(1), pp.010332~ (2020)
62. Harden EA, "Virucidal activity of polysaccharide extracts from four algal species against herpes simplex virus", Antivir Res, 83(3), pp.282~289 (2009)
63. Leibbrandt A, "Iota-carrageenan is a potent inhibitor of influenza A virus infection", PLOS ONE, 5(12), pp.e14320~ (2010)
64. Bansal S, "Iota-carrageenan and xylitol inhibit SARS-CoV-2 in cell culture", bioRxiv, ~ (2020)
65. Cheudjeu A, "Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19", Life Sci, 260, pp.118335~ (2020)
66. Stathis C, "Review of the use of nasal and oral antiseptics during a global pandemic", Future Microbiol, 16(2), pp.119~130 (2021)

관련 논문AI추천